Share on LinkedInShare on LinkedIn

ARTICLE · 01 MAY 2026

5 Costly IP Mistakes To Avoid

Greenberg Traurig
Greenberg Traurig
Contributor
Greenberg Traurig

Greenberg Traurig

Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States,...

View firm profile
Explore more from Greenberg Traurig

Patents serve as the fundamental currency of the medical technology industry, enabling companies to raise capital, form strategic alliances, and generate licensing revenue. Yet many medtech innovators fail to treat their intellectual property as a core business asset, risking the loss of competitive advantage and market exclusivity that could diminish the full value of their innovations.

United StatesIntellectual Property
 David J.  Dykeman
David J. Dykeman

Patents are the currency of the medical technology industry and fundamental to the success of any medtech company. A medtech company can leverage its intellectual property (IP) in many ways including: raising capital, entering into strategic alliances, using licensing to generate revenue, blocking competitors, and through joint ventures, mergers, acquisitions and initial public offerings (IPOs).

However, medtech innovators need to approach IP as a core business asset, or risk losing competitive advantage, market exclusivity, and ultimately the full value of their innovations.

LINKS

Read “5 Costly IP Mistakes to Avoid,” authored by David J. Dykeman, published by Medical Design & Outsourcing.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from